These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20629520)

  • 21. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
    Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
    Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
    [No Abstract]   [Full Text] [Related]  

  • 22. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 23. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
    Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
    Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
    [No Abstract]   [Full Text] [Related]  

  • 24. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE; Sausen M; Joseph A; Kingham BF
    Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment-free remission after stopping second-line dasatinib.
    Ross DM
    Lancet Haematol; 2015 Dec; 2(12):e506-7. PubMed ID: 26686401
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
    Gabriel I; Chaidos A; Sorouri J; Dannie E; Davis J; Goldman J; Apperley J; Marin D
    Leukemia; 2008 Aug; 22(8):1618-9. PubMed ID: 18305564
    [No Abstract]   [Full Text] [Related]  

  • 27. Glivec and beyond.
    Eur J Cancer; 2006 Aug; 42(12):1695. PubMed ID: 16998957
    [No Abstract]   [Full Text] [Related]  

  • 28. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 29. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
    Meera V; Jijina F; Shrikande M; Madkaikar M; Ghosh K
    Leuk Res; 2008 Oct; 32(10):1620-2. PubMed ID: 18420270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical management of dasatinib for maximum patient benefit.
    Galinsky I; Buchanan S
    Clin J Oncol Nurs; 2009 Jun; 13(3):329-35. PubMed ID: 19502192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The FDA approves new leukemia drug; expands use of current drug.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17338066
    [No Abstract]   [Full Text] [Related]  

  • 32. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
    Raanani P
    Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
    [No Abstract]   [Full Text] [Related]  

  • 33. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T315I, more or less, predicts for major molecular response: the devil is in the details!
    Mauro MJ
    Haematologica; 2013 May; 98(5):665-6. PubMed ID: 23633541
    [No Abstract]   [Full Text] [Related]  

  • 36. Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Stein BL; Smith BD
    Leuk Res; 2011 Sep; 35(9):1161-3. PubMed ID: 21782241
    [No Abstract]   [Full Text] [Related]  

  • 37. American Society of Hematology annual meeting.
    Fricker J
    Lancet Oncol; 2008 Jan; 9(1):13. PubMed ID: 18183660
    [No Abstract]   [Full Text] [Related]  

  • 38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 40. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
    Ali S; Sergeant R; O'Brien SG; Foroni L; Hedgley C; Gerrard G; Milojkovic D; Stringaris K; Khoder A; Alsuliman A; Gilleece M; Gabriel IH; Cooper N; Goldman JM; Apperley JF; Clark RE; Marin D; Rezvani K
    Blood; 2012 Jul; 120(3):697-8. PubMed ID: 22822001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.